- Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients2008 | First Faculty of Medicine
- Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients2008 | Publication without faculty affiliation
- Transforming growth factor-beta1 as a marker in patients with operable breast cancer2007 | First Faculty of Medicine
- Transforming growth factor-beta1 as a marker in patients with operable breast cancer2007 | Faculty of Physical Education and Sport
- Neoadjuvant treatment of operable breast cancers2011 | First Faculty of Medicine
- Transforming Growth Factor - beta 1 as a Marker in Patients with Operable Breast Cancer2007 | Publication without faculty affiliation
- Induction (neoadjuvant) systemic therapy for operable breast cancers: pros and cons2010 | First Faculty of Medicine
- Increased TGF-Beta 1 plasma level correlates with positive sentinel lymphnode in patients with operable breast cancerPublication without faculty affiliation
- A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)2021 | Publication without faculty affiliation
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial2017 | Publication without faculty affiliation